An announcement from Moleculin Biotech (MBRX) is now available.
Moleculin Biotech, Inc. is set to conduct a corporate update webcast to discuss its move to a Phase 3 pivotal trial for Annamycin in combination with Cytarabine, targeting the treatment of Acute Myeloid Leukemia (AML) in patients who haven’t responded to initial therapy. The webcast is scheduled for August 6, 2024, and aims to share progress and future plans for this promising treatment approach.
For an in-depth examination of MBRX stock, go to TipRanks’ Stock Analysis page.
